Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, beta 5 | Starlite/ChEMBL | References |
Homo sapiens | integrin, alpha V | References | |
Homo sapiens | integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | Starlite/ChEMBL | References |
Homo sapiens | integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | integrin alpha ps | integrin, alpha V | 1002 aa | 908 aa | 22.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Integrin alpha pat-2 precursor | 0.0369 | 0.2698 | 0.1672 |
Loa Loa (eye worm) | hypothetical protein | 0.029 | 0.1405 | 0.1405 |
Loa Loa (eye worm) | integrin beta-2 | 0.0817 | 1 | 1 |
Echinococcus granulosus | raf serine:threonine protein kinase | 0.0492 | 0.4695 | 0.6552 |
Brugia malayi | Raf kinase | 0.0475 | 0.4416 | 0.3631 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0492 | 0.4695 | 1 |
Echinococcus multilocularis | integrin beta 2 | 0.0602 | 0.6486 | 1 |
Toxoplasma gondii | 1,3-beta-glucan synthase component protein | 0.0446 | 0.3952 | 0.5 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.0569 | 0.5956 | 0.5956 |
Echinococcus granulosus | integrin beta 2 | 0.0602 | 0.6486 | 1 |
Loa Loa (eye worm) | raf kinase | 0.049 | 0.4656 | 0.4656 |
Loa Loa (eye worm) | hypothetical protein | 0.0279 | 0.1232 | 0.1232 |
Loa Loa (eye worm) | TKL/RAF/RAF protein kinase | 0.0279 | 0.1224 | 0.1224 |
Schistosoma mansoni | integrin beta subunit | 0.0475 | 0.4426 | 0.865 |
Echinococcus multilocularis | raf serine:threonine protein kinase | 0.0492 | 0.4695 | 0.6552 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.3 nM | Inhibitory concentration against alphaV-beta3 integrin using vitronectin ELISA assay. | ChEMBL. | 12482416 |
IC50 (binding) | = 1.3 nM | Inhibitory concentration against alphaV-beta3 integrin using vitronectin ELISA assay. | ChEMBL. | 12482416 |
IC50 (binding) | = 2000 nM | Inhibition of alphaIIb-beta3 integrin binding to fibrinogen in ELISA | ChEMBL. | 12482416 |
IC50 (binding) | = 2000 nM | Inhibition of alphaIIb-beta3 integrin binding to fibrinogen in ELISA | ChEMBL. | 12482416 |
IC50 (binding) | = 0.01 uM | Inhibition of alphaV-beta5 integrin binding to vitronectin in adhesion assay | ChEMBL. | 12482416 |
IC50 (binding) | = 0.01 uM | Inhibition of alphaV-beta5 integrin binding to vitronectin in adhesion assay | ChEMBL. | 12482416 |
IC50 (binding) | = 0.5 uM | Inhibition of alphaV-beta3 integrin binding to osteopontin in adhesion assay | ChEMBL. | 12482416 |
IC50 (binding) | = 0.5 uM | Inhibition of alphaV-beta3 integrin binding to osteopontin in adhesion assay | ChEMBL. | 12482416 |
Papp (ADMET) | = 4.2 | Apparent permeability coefficient was determined using caco-2 permeation assay | ChEMBL. | 12482416 |
Papp (ADMET) | = 4.2 | Apparent permeability coefficient was determined using caco-2 permeation assay | ChEMBL. | 12482416 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.